sexta-feira, 1 de julho de 2011

O caso DSK - a verdade revelada


A camareira mentiu e planejou a denuncia de assedio sexual. Noticia do NYT com a revelação de conversa telefônica faz Corte de NY rever e libertar DSK  

Strauss-Kahn Is Released as Case Teeters


Todd Heisler/The New York Times
Dominique Strauss-Kahn was released from house arrest on Friday.



Dominique Strauss-Kahn was released from house arrest on Friday as the sexual assault case against him moved one step closer to dismissal after prosecutors told a Manhattan judge that they had serious problems with the case.
Multimedia
Prosecutors acknowledged that there were significant credibility issues with the hotel housekeeper who accused Mr. Strauss-Kahn of trying to rape her in May. In a brief hearing at State Supreme Court in Manhattan, prosecutors did not oppose his release; the judge then freed Mr. Strauss-Kahn on his own recognizance.
The development represented a stunning reversal in a case that reshaped the French political landscape and sparked debate about morals, the treatment of women and the American justice system. The case could also alter the political fortunes of Cyrus R. Vance Jr., the Manhattan district attorney, who is just a year and a half into his tenure and was facing his most highly publicized case to date.
Mr. Strauss-Kahn, 62, was considered a strong contender for the French presidency before being accused of sexually assaulting the housekeeper who went to clean his luxury suite at the Sofitel New York. After his arrest, Mr. Strauss-Kahn resigned his position as managing director of the International Monetary Fund.
From Mr. Strauss-Kahn’s first court appearance on May 16, Mr. Vance’s office expressed extreme confidence in its case. At that hearing, an assistant district attorney said that “the victim provided very powerful details consistent with violent sexual assault committed by the defendant.” Those accounts varied greatly from what prosecutors revealed on Friday, acknowledging publicly for the first time that the case was not as strong as initially suggested. In a letter sent to Mr. Strauss-Kahn’s lawyers and filed with Justice Michael J. Obus on Friday, prosecutors outlined some of what they had discovered about Mr. Strauss-Kahn’s accuser, poking holes in her account and her background.
Prosecutors disclosed that the woman had admitted lying in her application for asylum from Guinea; according to the letter, she “fabricated the statement with the assistance of a male who provided her with a cassette recording” that she memorized. She also admitted that her claim that she had been the victim of a gang rape in Guinea was also a lie.
The woman also admitted to the prosecutors that she had misrepresented her income to qualify for her housing, and had declared a friend’s child — in addition to her own daughter — as a dependent on tax returns to increase her tax refund.
The housekeeper admitted that she lied about what happened after the episode on the 28th floor of the hotel. She had initially said that after being attacked, she had waited in a hallway until Mr. Strauss-Kahn left the room; she now admits that after the episode, she cleaned a nearby room, then returned to Mr. Strauss-Kahn’s suite to clean there. Only after that did she report to her supervisor that she had been attacked.
The woman’s lawyer, Kenneth Thompson, gave a lengthy retort outside the courtroom in which he conceded problems with her credibility, but insisted that she was still the victim of an attack, saying that her version of events has never wavered. He said some evidence, such as bruising she had suffered, was consistent with a nonconsensual encounter. And he said her decision to clean a room was consistent with someone who was confused and upset in the wake of an attack. Questions are sure to be raised about how swiftly and vigorously prosecutors proceeded with the case, as many in France questioned whether there was a rush to judgment with Mr. Strauss-Kahn.
While prosecutors have not yet dismissed the case, Mr. Strauss-Kahn will now be able to move about the country more freely; although prosecutors will retain his passport, most of his restrictive bail conditions have been lifted. Under those conditions, he was required to stay in a Lower Manhattan town house under armed guard and wearing an ankle monitor. He could only leave for certain reasons and had to notify prosecutors when he left.
Although forensic tests found unambiguous evidence of a sexual encounter between Mr. Strauss-Kahn and the woman, prosecutors now do not believe much of what the accuser has told them about the circumstances or about herself.
Since her initial allegation on May 14, the accuser has repeatedly lied, one of the law enforcement officials said.
According to the two officials, the woman had a phone conversation with an incarcerated man within a day of her encounter with Mr. Strauss-Kahn in which she discussed the possible benefits of pursuing the charges against him. The conversation was recorded.
That man, the investigators learned, had been arrested on charges of possessing 400 pounds of marijuana. He is among a number of individuals who made multiple cash deposits, totaling around $100,000, into the woman’s bank account over the last two years. The deposits were made in Arizona, Georgia, New York and Pennsylvania.

escolha de gestores de Universidades -Folha de São Paulo- Tendências e Debate


TENDÊNCIAS/DEBATES

O espelho dos EUA e a universidade nacional

PEDRO MEIRA MONTEIRO

Convém olhar o modelo dos EUA por dentro; a sedução dele raramente é acompanhada pelo conhecimento das suas verdadeiras engrenagens

No dia 22 de junho, neste espaço, Rogério Cezar de Cerqueira Leite lançou uma provocação: como a universidade brasileira pode subir no "ranking" de qualidade?
Para o físico brasileiro, a resposta aponta para os Estados Unidos e para a Inglaterra.
Sua vantagem estaria em que, nas mais qualificadas universidades desses países, (1) o órgão colegiado supremo é formado por membros externos à academia, (2) a escolha de reitores está protegida da força da "corporação interna", (3) há mecanismos de proteção à "endogenia", com escolha de professores titulares de fora da própria universidade, e (4) a estabilidade se alcançaria apenas no fim da carreira.
A sedução dos modelos estrangeiros raramente é acompanhada pelo conhecimento de suas engrenagens. Não há dúvida de que a academia dos EUA é, no geral, mais eficiente que a brasileira.
Contudo, o elogio desse ambiente supostamente menos personalizado (protegido do perigo da "endogenia") resulta, quando se olha para o caso brasileiro, no aviltamento das instâncias internas de decisão, como se fazer política dentro da universidade fosse tarefa espúria, limitada a "grupelhos" de professores improdutivos.
A alternativa seria, então, abrir a universidade e romper a sua lógica endogâmica. Segundo Cerqueira Leite, as instituições de pesquisa em mira têm, como órgão decisório máximo, um pequeno grupo de "cidadãos prestantes externos à universidade". Trata-se do "board of trustees" (algo como o conselho das empresas estatais no Brasil).
Porém, os "trustees" (reveladora expressão!) são ex-alunos que se tornaram excelentes em suas profissões e que não raro fizeram fortuna, literalmente.
Esta, a verdadeira lógica endogâmica da universidade nos EUA: o martelo que bate e aprova as monumentais decisões orçamentárias pertence a ex-alunos, o que faz com que toda a máquina funcione para agradar os alunos de hoje, que serão os doadores e os "trustees" de amanhã. Endogenia pura, mediada pelo dinheiro.
Mas as decisões que chegam à mesa dos "trustees" são tomadas por um grande colegiado de professores, que em universidades mais aguerridas é chamado de "Senado". Não se faz ciência sem política.
Outra ilusão é pensar que a carreira docente estaria protegida da endogenia. No entanto, a notória mobilidade dos acadêmicos nos EUA não impede o favorecimento de grupos e de agendas internas aos vários campos do saber.
A contratação de um colega "senior" se dá a partir de uma decisão interna dos membros "senior" de um departamento, a ser corroborada pelo órgão colegiado por uma consulta externa a membros do "campo". Um misto de ingerência "externa" e "interna", portanto.
Já a noção de que nas universidades americanas o docente só alcança estabilidade "no fim da carreira" é simples engano. Como no Brasil, há um período probatório, em geral de seis anos, antes que se ganhe esse selo vitalício.
A diferença é que o período probatório é para valer, existindo aí julgamento "externo", com consultas sigilosas a colegas de outras universidades. Já a justiça desse sistema de promoção é em si um tema espinhoso.
Em suma, se os vizinhos ao Norte nos oferecem um modelo, convém olhá-lo por dentro. Do contrário, seremos vítimas da ilusão de que nossa histórica ineficiência é o inverso da eficiência que atribuímos a eles.
Como se o mundo, ao Sul, estivesse de ponta-cabeça.
PEDRO MEIRA MONTEIRO é professor de literatura brasileira na Universidade Princeton (EUA) e autor de "Um Moralista nos Trópicos" (Boitempo).

Os artigos publicados com assinatura não traduzem a opinião do jornal. Sua publicação obedece ao propósito de estimular o debate dos problemas brasileiros e mundiais e de refletir as diversas tendências do pensamento contemporâneo. debates@uol.com.br


Texto Anterior: José Sarney: Cruzado: 25 anos

Próximo Texto: Luiz Fernando Emediato: Eike, o aventureiro atrevido

Índice | Comunicar Erros

corrupção no Brasil- Global integrity- Transparência Brasil e MPF

A corrupção tem raizes históricas no Brasil, não é recente, nem também é maior, mas em momentos de grandes obras públicas com finaciamentos do Estado ( com dinheiro do seu imposto) é preciso discutir esse tema com prioridade.

Leis frágeis, fiscalização irregular, falta de indicadores de superfaturamento, dependência de financiamento de campanhas eleitorais por empresas que se beneficiam no pós eleição, excesso de apelações judiciais resultam em incentivos à corrupção.

É o momento de discutirmos e fazermos da Ética e transparência publica bandeiras politicas para eleger ou releger candidatos. Não adianta reclamar sobre corrupção se você votou em candidato sabidamente corrupto. Se voce fez isso, você contribuiu. Mudar sua atitude, muda também o Brasil.

Os órgãos de controle fazem o que podem.

Agite, discuta e não eleja candidatos corruptos, assim você transforma o Brasil.

Recomendo os sites e analises interessantes sobre corrupção
http://www.transparencia.org.br/
neste site voce pode acessar dados sobre financiamento de campanhas eleitorais e varios outros temas relacionados, alé de um manual sobre mapa de riscos
A Global Integrity traz um outro tipo de análise com graficos e um indicador em cores (veja graficos e acesse site)






2009 ASSESSMENT

Brazil: 2009
This peer-reviewed country report includes:

Integrity Indicators Scorecard: Scores, scoring criteria, commentary, references, and peer review perspectives for more than 300 Integrity Indicators.

Reporter's Notebook: An on-the-ground look at corruption and integrity from a leading local journalist.

Corruption Timeline: Ten years of political context to today's corruption and integrity issues.

Brazil's performance on key governance and anti-corruption measures continues to serve up a mixed picture. The country earns strong ratings in the areas of civil society, voting and elections, privatization, and anti-corruption legal regulations. The Brazilian Court of Audit is very active in opening investigations into financial irregularities, with "all proceedings, minutes, and questions… published on [its] website." Unfortunately, there are several dimensions of governance that remain in need of significant improvement. While a constitutional right to access government information exists, no law or instutitional mechanism is in place in Brazil to operationalize that right in practice. The "availability of information," especially in the executive branch, "varies tremendously" while federal bodies are generally more responsive to information requests than agencies at the state and municipal levels. Donations to political parties and individuals are also weakly regulated. Since the limits on individual donations are based on a percentage of one's income, for instance, "wealthy individuals might exercise a decisive influence on an election, especially [at] the local level." Furthermore, the Brazilian ombudsman office is not independent and is instead subsumed under the Office of the Comptroller General and appointed by the executive. Whistle-blowing protections in Brazil remain virtually non-existent as most governmental bodies "refuse to accept anonymous charges."


Visit Global Integrity Commons for recent analysis on Brazil.



mais detalhes acesse
http://report.globalintegrity.org/Brazil/2009

quarta-feira, 29 de junho de 2011

Investimento no Brasil - Finantial Times





In Brazil, the chances are that if you eat a burger, go to college or travel to Miami, you will be putting money into the pockets of private equity firms.
A boom in the industry in Latin America over the past few years has led to a host of new deals, with a Brazilian private equity firm, Vinci Partners, holding the local franchise for Burger King, and others, such as Advent International, targeting Brazil’s fast-growing education sector.

Carlyle’s South American buy-out team, meanwhile, made its first investment in the region last year in CVC Brasil Operadora e Agência de Viagens, the region’s biggest tour operator.
Most of the large companies have already set up offices in Brazil, or like Kohlberg Kravis Roberts and TPG, are looking to do so.
“The number of managers able to write $100m cheques here have multiplied by five,” said R. Duncan Littlejohn, managing director at Paul Capital in São Paulo.
The big private equity companies had been among the last to come back to the country because of their memory of previous hardships.
While the last five years have been upbeat – comanies raised $8.1bn for Latin America as a whole last year and are expected to have $10bn-$11bn available for investment in Brazil alone by the end of 2011 – it has not always been this good.
During the last boom in the 1990s, they raised about $6bn to invest in Brazil, according to Advent International. Then the internet bubble imploded, Brazil suffered a currency crisis and the leftist presidential candidate Luiz Inácio Lula da Silva came to power.
During the early 2000s, the market plunged and the downturn was so severe that some funds returned their money to investors and turned their backs on Brazil.
Patrice Nogueira Baptista Etlin, managing partner in São Paulo for Advent International, which opened in Brazil in 1997, said: “The market was abandoned in what we call in our industry the ‘nuclear winter’” .
But Mr Lula da Silva followed through on economic reforms started by his predecessor, Fernando Henrique Cardoso, including passing laws that reformed Brazil’s stock market and improved corporate governance among listed companies.
This paved the way for an increase in initial public offerings, that in turn provided an important platform for private equity’s return.
IPOs in Brazil increased from only about six between 1994 and 2004 to about 200 since then.

The industry received a scare again in 2009 when the global financial crisis hit Brazil. But the economy recovered quickly, leading to a rush of private equity funds into the country last year.
High-profile investments included JPMorgan’s acquisition of control of Gávea Investimentos in Rio, and Blackstone’s buying a stake in another local fund, Pátria Investimentos.
The increase in private equity money chasing deals in Brazil has led to concern that the market is becoming saturated. But Brazil’s private equity environment remains relatively under-developed compared with the US.
Personal relationships between companies and individual entrepreneurs or business families remain key and there are fewer open auctions of companies of the kind seen for most deals in the US.
Advent’s Mr Etlin says there are an estimated 50,000 companies in Brazil with revenue of R$50m ($31m) or more a year. “It’s a huge aquarium,” he said.
Brazil also has the advantage of being the most culturally similar emerging market for US and European funds, says Cate Ambrose, president of Latin American Venture Capital Association.
She said: “Brazil is much closer to the European and US business culture of working with financial investors, building up the company and eventually selling it”.
To be sure, Brazil has important differences with developed markets. Its high interest rates make highly leveraged transactions less attractive. Brazil’s taxes on financial transactions also make it expensive to import capital.
Its smaller and medium-sized family-run companies have also traditionally been suspicious of outside investors.
Yet this is changing as they seek growth capital, says Marcelo Di Lorenzo, managing director at 3i Brasil. Family businesses are becoming more ambitious about realising value.

terça-feira, 28 de junho de 2011

vacina para tuberculose - Science


TUBERCULOSIS
Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants
Martin O. C. Ota1,*, Aderonke A. Odutola1, Patrick K. Owiafe1, Simon Donkor1, Olumuyiwa A. Owolabi1, Nathaniel J. Brittain2, Nicola Williams3, Sarah Rowland-Jones1, Adrian V. S. Hill2, Richard A. Adegbola4 and Helen McShane2
+ Author Affiliations

1Bacterial Diseases Programme, Medical Research Council Unit, P. O. Box 273, Banjul, The Gambia.
2Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK.
3Centre for Statistics in Medicine, Wolfson College, Linton Road, Oxford OX2, UK.
4Bill & Melinda Gates Foundation, Seattle, WA 98102, USA.
↵*To whom correspondence should be addressed. E-mail: mota@mrc.gm
New tuberculosis vaccines are urgently needed to curtail the current epidemic. MVA85A is a subunit vaccine that could enhance immunity from BCG vaccination. To determine MVA85A safety and immunogenicity as well as interactions with other routine vaccines administered in infancy, we randomized healthy 4-month-old infants who had received Bacille Calmette-Guérin at birth to receive Expanded Program on Immunization (EPI) vaccines alone, EPI and MVA85A simultaneously, or MVA85A alone. Adverse events were monitored throughout. Blood samples obtained before vaccination and at 1, 4, and 20 weeks after vaccination were used to assess safety and immunogenicity. The safety profile of both low and standard doses was comparable, but the standard dose was more immunogenic and therefore was selected for the second stage of the study. In total, 72 (first stage) and 142 (second stage) infants were enrolled. MVA85A was safe and well tolerated and induced a potent cellular immune response. Coadministration of MVA85A with EPI vaccines was associated with a significant reduction in MVA85A immunogenicity, but did not affect humoral responses to the EPI vaccines. These results provide important information regarding timing of immunizations, which is required for the design of infant efficacy trials with MVA85A, and suggest that modifications to the standard EPI schedule may be required to incorporate a new generation of T cell–inducing vaccines.

INTRODUCTION

Globally, tuberculosis (TB) continues to be a disease of major public health importance (1) despite widespread coverage by Bacille Calmette-Guérin (BCG) vaccination; the persistent TB disease burden underlines the inadequacy of the BCG vaccine to protect against TB in adults. As such, there is an urgent need for a more effective vaccine (2). However, BCG protects against severe forms of TB in childhood and has nontargeted beneficial effects, including improving child survival, increasing responses to hepatitis B and oral polio vaccines administered in infancy, preventing allergic disorders, and protecting against leprosy (3–5). Consequently, it is logical to deploy a vaccination strategy against TB that includes BCG.

MVA85A is a TB vaccine designed to enhance BCG (6, 7). Modified vaccinia virus Ankara (MVA) is a strain of vaccinia virus that is replication-incompetent in human cells. MVA85A is a recombinant MVA strain that encodes the immunodominant mycobacterial antigen 85A (8). When administered after BCG, MVA85A can provide enhanced protection against TB challenge in animal models (9). MVA85A has been shown to be safe and highly immunogenic in clinical trials in adults in the UK, Gambia, and South Africa (6, 7, 10, 11).

The prevalence of TB in infants, children, and adolescents in most developing countries means that any effective TB vaccine should be given early in life, which coincides with the period that other childhood vaccines are given according to the Expanded Program on Immunization (EPI) schedule. The EPI program has been highly successful at increasing the coverage of existing licensed vaccines across the developing world. Integrating a new TB vaccine within the EPI schedule would facilitate deployment and uptake. However, before any vaccines can be coadministered, it is important to evaluate potential interference between the vaccines that could affect the induction of a protective immune response (12) because coadministration with EPI vaccines may diminish the potency of novel vaccine candidates (12). Here, we assessed the safety and immunogenicity of MVA85A in 4-month-old infants and, in parallel, evaluated potential interference with EPI schedule vaccines routinely administered at this age.

RESULTS

Study profile
We screened 350 infants in total (Fig. 1). Of these, 136 (39%) failed screening. Reasons for exclusion are listed in table S1. The first 36 infants were enrolled in the low-dose group (stage 1a), and the next 36 infants were enrolled in the standard-dose group (stage 1b). After safety and immunogenicity analyses of the stage 1 data, the standard dose was selected for the remainder of the study (stage 2), in which 142 infants were enrolled. All enrolled infants in each stage were randomized to one of the three study groups (Fig. 1). Demographic details, age at BCG vaccination, body weight, age at enrollment, and sex ratio were comparable across the three study groups (table S2). Stage 3 was initially planned in the protocol as an expansion of stage 2, if necessary. However, because the interference results from stage 2 were clear, the protocol was amended and stage 3 was not performed. Study duration was from October 2006 to October 2009.
Fig. 1
Consort flowchart. A consort diagram of the study from initial discussion: progressing from low dose to standard dose listing the number of participants for each stage and group of the study. During stage 2 of the study, 47 infants were randomized to group 2, but 48 received treatment because 1 infant inadvertently received EPI and MVA85A vaccines simultaneously. Therefore, in group 3, 48 were randomized but 47 received treatment.

Stage I safety results
To select a dose to be used for the rest of the study, we compared the safety profile between the low-dose (n = 24, excluding EPI-only controls) and the standard-dose (n = 24) MVA85A recipients in stage 1a and stage 1b, respectively (tables S3 to S5). Two days after vaccination, a significantly higher proportion of the standard-dose recipients had redness and pain, but not desquamation or swelling, at the site of vaccination in group 3 (MVA85A alone) but not group 2 (EPI + MVA85A) (table S3). None of the MVA85A recipients had pain that was greater than grade 1. Seven days after vaccination, a significantly higher proportion of subjects had redness in group 3 and desquamation in groups 2 and 3. Pain and swelling at this time point were comparable. There were no differences after vaccination in systemic adverse events (AEs) or hematological or biochemical values between stage 1a and 1b (tables S4 and S5), except for alanine transaminase, which was significantly higher in stage 1b than 1a in group 2 but not group 3, even though these values were still within normal limits (P = 0.018; table S5). There was no difference between all three groups when stages 1b and 2 were combined (table S5).

MVA85A dose response
In stage 1, the area under the curve (AUC) [interquartile range (IQR)] for the Ag85A immune response induced by low-dose MVA85A (stage 1a) was 223 (54 to 421) in group 2 and 1191 (129 to 1807) in group 3 (Table 1). The standard-dose group (stage 1b) induced significantly higher responses than low dose in group 2, as depicted by an AUC (IQR) of 1302 (742 to 3401) (P = 0.0005), and group 3, AUC of 4515 (3118 to 5543) (P = 0.0012 by Mann-Whitney U test). Responses in group 1 (EPI alone) did not differ across the three time points measured (Table

Because higher immunogenicity and a comparable safety profile were seen when results from stage 1a and 1b were compared, a decision to continue to use the standard dose in stage 2 was made and was approved by the ethical committees. Safety and immunogenicity data from stages 1b and 2 were therefore combined for the further data analyses.

MVA85A safety data
Safety data were collected from all infants (tables S3 to S5). MVA85A was safe and well tolerated. Consistent with previous data, most subjects developed mild local and systemic AEs (6, 10, 13) (tables S3 and S4). Two days after vaccination, there was a significant increase in the number of infants in group 2 with excessive crying and vomiting (P = 0.035 for both, table S4 by χ2 test). Seven days after vaccination, all systemic AEs had resolved to nonsignificant differences among all three groups. There were no significant differences in the biochemical and hematological indices among the three groups, either at baseline or 1 week after vaccination (table S5). Infants’ mean weights at 9 and 12 months after vaccination were comparable across the three groups (table S2).

Seven serious adverse events (SAEs) occurred during the study. The frequency of SAEs was comparable across the three groups. The three SAEs in group 1 were malaria, urinary tract infection, and bronchopneumonia; the two SAEs in group 2 were both bronchopneumonia; and the two SAEs in group 3 were diarrhea and bronchopneumonia. None of these SAEs was judged to be related to study vaccine.

Effect of EPI vaccines on MVA85A immunogenicity
To evaluate potential interference between EPI vaccines and MVA85A, we compared the ex vivo interferon-γ (IFN-γ) enzyme-linked immunospot (ELISPOT) response to the Ag85A peptide pool between groups 2 and 3 (Fig. 2). Baseline immune responses were comparable. There were significantly higher responses at 1 (P = 0.0138), 4 (P = 0.0127), and 20 (P = 0.0093) weeks after vaccination in group 3 than in group 2 with the Mann-Whitney U test. Comparing the median (range) of the AUC, group 3 was significantly higher than group 2 [median difference, 1374; 95% confidence interval (CI), 499 to 2354; P = 0.0010], indicating that the average response was higher over the entire period of study. Despite the effect of the EPI vaccines, the cellular immune response to MVA85A remained significantly higher 20 weeks after vaccination compared to baseline in both group 2 (P < 0.0001) and group 3 (P < 0.0001). Fig. 2 Immunogenicity of MVA85A. Immunogenicity was measured by ex vivo IFN-γ ELISPOT assay to a single pool of antigen 85A peptides. The figure compares responses in group 2 (EPI + MVA85A, filled circles) and group 3 (MVA85A alone, open circles) at baseline and 1, 4, and 20 weeks after vaccination. The horizontal lines indicate median values. The baseline median (IQR) of purified protein derivative (PPD) responses was 75 (45 to 193), 90 (25 to 181.8), and 90 (42.5 to 212.5) for groups 1, 2, and 3, respectively, and was not significantly different from each other. The median (IQR) difference AUC for the PPD responses over the 5 months after MVA85A vaccination (groups 2 and 3) or not (group 1) was 467 (−50 to 1039; P = 0.073) between groups 1 and 2, 737 (158 to 1643; P = 0.010) between groups 1 and 3, and 345 (−275 to 1088; P = 0.265) between groups 2 and 3 by Mann-Whitney U test. Interference of MVA85A vaccines with antibody responses to EPI vaccines The concentrations of antibodies specific to each vaccine component in the DTwP-Hib (diphtheria, tetanus, whole-cell pertussis, and Haemophilus influenzae type b) and hepatitis B regimen were compared between groups 2 and 1. The geometric mean (GM) or median antibody titer to each of the antigens was not significantly different between the groups (Table 2). Further analysis with antibody titers categorized according to threshold values also showed no significant difference in the proportions achieving protective levels between the two groups. View this table: In this window In a new window Table 2 Antibody level to EPI vaccines measured at the age of 5 months after three doses of DTwP-Hib and hepatitis B at ages 2, 3, and 4 months according to study groups. The table shows geometric means (GM) with 95% confidence interval (CI). Hepatitis B surface antigen and pertussis toxoid data were not normally distributed after log transformation and are therefore presented as medians and ranges. Subanalysis categorizes antibody titers according to known protective threshold levels. There are no antibody data from the infant randomized to group 3 but treated as in group 2. Note that the assay for hepatitis B had a maximum cutoff of 1000 mIU/ml. Effect is the back-transformed coefficient unless where medians were used, and it represents the ratio of the effect on antibody titer of having EPI with MVA85A concomitantly compared to EPI vaccines only. DISCUSSION This clinical trial evaluates the administration of an MVA-based TB vaccine in 4-month-old infants, as well as interactions between MVA85A and routine EPI schedule vaccines. The higher proportion of infants with local AEs in the standard-dose group compared to the low-dose group was consistent with previous studies using MVA85A and other recombinant MVAs, where there is a dose-response relationship between vector dose and local AE profile (13, 14). Most AEs were comparable between the two doses 7 days after vaccination. A significantly higher proportion of infants that received the EPI + MVA85A vaccines simultaneously (group 2) showed an increase in vomiting and crying when compared to the EPI-alone (group 1) or MVA85A-alone (group 3) groups. Because these events were not more frequent in the infants receiving MVA85A alone, compared to the group receiving EPI vaccines alone, this finding may be a result of inflammatory processes at two injection sites rather than one. It may also be due to the EPI + MVA85A group receiving a relatively higher antigenic load, because they received six vaccines compared to either five or one in the EPI and MVA85A groups, respectively (15, 16). These events were all mild and resolved by day 7 after vaccination. Both doses of MVA85A induced a significant antigen-specific immune response compared to unvaccinated controls. The peak response occurred 7 days after vaccination as previously described (6, 7, 10, 11). The cellular immune response to MVA85A was significantly lower when given simultaneously with the EPI vaccines compared to when administered alone. This difference may relate to interference between MVA85A and the EPI vaccines themselves or, more likely, the alum adjuvant they contain. Alum is the only licensed adjuvant for human use and is associated with the induction of a T helper type 2 (TH2)–dominated immune response (17, 18), which reciprocally inhibits TH1-type responses (19). The increased response to PPD in group 3 (MVA85A without EPI vaccines) is likely to be related to the enhanced response to antigen 85A seen in this group, because antigen 85A is a component of PPD. Because IFN-γ is a key effector molecule in protective immunity against intracellular organisms, including Mycobacterium tuberculosis (20, 21), our finding has implications for the use of MVA for vaccines against other pathogens, for viral vectors in general, and for TH1 type–inducing vaccines. We do not fully understand the mechanisms responsible for the interaction of these vaccines or the biological implications; however, this finding indicates that the internal milieu at the time of processing antigens might affect the magnitude of the response. The coadministration of EPI vaccines with the malaria vaccine candidate RTS,S/AS02, which contains a TH1-biased adjuvant, led to lower levels of antibody responses to the malaria antigen than in regimes that avoided coadministration (12). The benefits of introducing a new vaccine within the EPI schedule include reduced clinic visits, increased coverage, and possible enhanced immunogenicity of the vaccines (4). However, these favorable outcomes must be balanced against potential negative immunological interactions between simultaneously administered vaccines. At present, our data do not support concomitant administration of MVA85A with licensed EPI vaccines, and this finding has supported the assessment of MVA85A administered outside of the EPI schedule in an ongoing Phase IIb efficacy trial in infants (clinicaltrials.gov trial identifier NCT00953927). However, although we have demonstrated a statistically significant reduction in immunogenicity by IFN-γ response when MVA85A is co-administered with the EPI vaccines, the clinical significance of this finding is uncertain in the absence of a validated immunological correlate of protection. Further work is needed to evaluate whether such interference can be overcome by increasing vaccine dose, thus retaining the advantages of concomitant administration. This study has demonstrated that MVA85A is safe and well tolerated and induces an immune response considered protective against M. tuberculosis. It illustrates the importance of doing interference studies with new vaccines and evaluating bidirectional interference. Trials such as this are essential with new TB vaccines and T cell–inducing vaccines in general. They provide essential information needed for the design of efficacy trials. More generally, our findings highlight that modifications to the standard EPI regime may be needed to incorporate a new generation of T cell–inducing vaccines. MATERIALS AND METHODS Study site and recruitment of study participants This study was conducted at Sukuta Health Centre, Gambia. The study was approved by the Gambian government/Medical Research Council Joint Ethics Committee and Oxford Tropical Research Ethics Committee. Preliminary discussions about the trial were conducted with parents shortly after an infant’s birth, and information sheets were distributed. When these infants attended for their EPI schedule vaccines at age 3 months (visit 1), they were enrolled provided they fulfilled the following criteria: They were healthy, had received BCG within the first 4 weeks of life and had a typical BCG scar, had received their EPI schedule immunizations according to the national program (DTwP-Hib at 2 and 3 months, oral polio vaccine at birth and 2 and 3 months, hepatitis B at birth and 2 months), and their parents had given written informed consent. A blood sample was taken for baseline safety and immunogenicity. An independent statistician randomly assigned participants in a 1:1:1 ratio in blocks of six to one of the three study groups. A unique number for each participant detailing the treatment group was placed in a sealed opaque envelope and arranged serially. At 4 months of age (visit 2), when a child fulfilled the eligibility criteria, one of the study team selected the next envelope to determine study number and treatment group. The EPI vaccines given at this time point were the third doses of DTwP-Hib and hepatitis B. This trial was conducted according to the principles of the International Conference on Harmonisation–Good Clinical Practice guidelines, was externally monitored by an independent contract research organization, and is registered on clinicaltrials.gov (NCT00480454). Vaccines MVA85A was administered intradermally on the side ipsilateral to the BCG vaccination. All EPI vaccines were given intramuscularly apart from the oral polio vaccine. After MVA85A injection, the vaccination site was covered to minimize virus dissemination into the environment. Because this was the first trial with MVA85A in infants, we commenced this trial with low-dose MVA85A [2.5 × 107 plaque-forming units (PFUs)]. Once we had established safety with this dose in 24 infants, we then administered 5 × 107 PFU (the standard dose of MVA85A used previously) to the next 24 infants. A dose of 5 × 107 PFU was selected for the remainder of the study after analysis of the safety data. We obtained ethical approval before proceeding to each stage of the study. MVA85A was manufactured under Good Manufacturing Practice conditions by Impfstoffwerk Dessau-Tornau, Germany. Concomitant licensed EPI vaccines were obtained from the same source as the Ministry of Health of Gambia through the World Health Organization. Reactogenicity Each infant’s vital signs were monitored before vaccination and 30 and 60 min after vaccination. Thereafter, the dressing over the injection site was removed. Trained field workers visited the infants at home daily for the following 2 days to administer a reactogenicity questionnaire to the parents/guardians that included history of fever, vomiting, diarrhea, reduced feeding, and excessive crying. The field worker also examined the infant for expected local AEs (swelling, tenderness, redness, and desquamation at the site of injection for MVA85A) and fever. Pain at the injection site was graded on a scale of 0 to 3 (where 0 = no pain, 1 = painful to touch, 2 = partial restriction of activities, and 3 = unable to use the limb). Systemic and laboratory AEs were evaluated in all three study groups. Follow-up visits Subjects were reviewed 1 week after MVA85A administration (visit 3), corresponding to the time of peak MVA85A immune response reported previously (6, 7, 10, 11). Blood samples were obtained from all study participants before vaccination with the EPI vaccines deferred from visit 2 for group 3. Local and systemic reactogenicity in the first week after vaccination was recorded. Subsequent visits for immune responses were at the ages of 5 (visit 4) and 9 (visit 5) months. The protocol was amended to include additional visits at 12 (visit 6) and 18 (visit 7) months to monitor longevity of responses to MVA85A. Data from these visits will be reported in a separate manuscript. In all scheduled visits, solicited and unsolicited AEs were recorded and physical examinations were conducted. Blood samples were taken at each visit apart from visit 6. Parents and guardians were encouraged to take their infants to the trial clinic or Medical Research Council clinic with their study ID cards if their infant was unwell during the study. Any such visit was reported immediately to the trial team. LABORATORY METHODS MVA85A immunogenicity Immunogenicity of MVA85A was determined by measuring the frequency of IFN-γ spot-forming units (SFUs) by ex vivo ELISPOT assay (10). Briefly, peripheral blood mononuclear cells (PBMCs) suspended in 5% human AB serum in RPMI were seeded at 2 × 105 cells per 100 μl per well in duplicates and incubated in the presence of the antigen or controls. A pool of 15-mer peptides spanning the Ag85A protein (66 peptides that overlapped by 10 amino acids; 2 μg/ml each) and M. tuberculosis PPD (10 μg/ml) were used as recall antigens. Medium alone served as a negative control, whereas phytohemagglutinin (10 μg/ml) was the positive control. The number of IFN-γ SFU counted in each well was automatically entered into a database minus background (medium wells). When responses were too numerous to quantify, a maximum cutoff value of 200 spots per well or 1000 SFU per million PBMCs was assigned. EPI vaccine antibody measurement Antibody (immunoglobulin G) concentrations against diphtheria toxoid, tetanus toxoid, pertussis (toxoid and filamentous hemagglutinin), Haemophilus influenzae type b capsular polysaccharide, and hepatitis B surface antigen were measured by standard enzyme-linked immunosorbent assays (ELISAs) at the Health Protection Agency Immunoassay Laboratory, UK. For each antigen, sera were titrated against known concentrations of specific antibodies in standard sera samples. All laboratory assays were done blinded to the child’s study group. Data management and statistical analyses Data were double-entered into an Access database and manually validated. For categorical variables, data were summarized using numbers and percentages, and groups were compared with the χ2 test or, for small numbers, Fisher’s exact test. For continuous, normally distributed data, the mean and SD were used to summarize data, and groups were compared with an analysis of variance (for comparison of three groups) or a t test (for comparison of two groups). In the case of non-normally distributed data, a Kruskal-Wallis (for comparison of three groups) or Mann-Whitney U test (for comparison of two groups) was used. Comparisons between time points within a group were made with Wilcoxon matched-pairs signed-rank test. Such data were summarized with medians and 25th and 75th percentiles. In the case where a log transformation resulted in normally distributed data, the GM was presented and groups were compared with a t test. An AUC analysis was used to assess for overall differences in response over the follow-up period. Subjects were analyzed according to the treatment they received, rather than the group to which they were randomized. Analyses were done with Stata Release 10 statistical software (Stata). SUPPLEMENTARY MATERIAL www.sciencetranslationalmedicine.org/cgi/content/full/3/88/88ra56/DC1 Table S1. Reasons for exclusion of infants screened for participation. Table S2. Demographic and baseline characteristics of subjects by study group. Table S3. Comparison of number (percent) of local adverse events between study groups in stages 1a, 1b, and 2. Table S4. Comparison of number (percent) of systemic adverse events between study groups in stages 1a, 1b, and 2. Table S5. Comparison of biochemistry and hematology parameters [mean (SD)] between study groups in stages 1a, 1b, and 2. Citation: M. O. C. Ota, A. A. Odutola, P. K. Owiafe, S. Donkor, O. A. Owolabi, N. J. Brittain, N. Williams, S. Rowland-Jones, A. V. S. Hill, R. A. Adegbola, H. McShane, Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants. Sci. Transl. Med. 3, 88ra56 (2011).
REFERENCES AND NOTES

↵ C. Dye, C. J. Watt, D. M. Bleed, S. M. Hosseini, M. C. Raviglione, Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 293, 2767–2775 (2005). Abstract/FREE Full Text
↵ G. A. Colditz, T. F. Brewer, C. S. Berkey, M. E. Wilson, E. Burdick, H. V. Fineberg, F. Mosteller, Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271, 698–702 (1994). Abstract/FREE Full Text
↵ M. L. Garly, C. L. Martins, C. Balé, M. A. Baldé, K. L. Hedegaard, P. Gustafson, I. M. Lisse, H. C. Whittle, P. Aaby, BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG? Vaccine 21, 2782–2790 (2003). CrossRefMedlineWeb of Science
↵ M. O. Ota, J. Vekemans, S. E. Schlegel-Haueter, K. Fielding, M. Sanneh, M. Kidd, M. J. Newport, P. Aaby, H. Whittle, P. H. Lambert, K. P. McAdam, C. A. Siegrist, A. Marchant, Influence of Mycobacterium bovis bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination. J. Immunol. 168, 919–925 (2002). Abstract/FREE Full Text
↵ S. P. Zodpey, S. N. Shrikhande, S. W. Kulkarni, B. R. Maldhure, Scar size and effectiveness of Bacillus Calmette Guerin (BCG) vaccination in the prevention of tuberculosis and leprosy: A case-control study. Indian J. Public Health 51, 184–189 (2007). Medline
↵ T. Hawkridge, T. J. Scriba, S. Gelderbloem, E. Smit, M. Tameris, S. Moyo, T. Lang, A. Veldsman, M. Hatherill, L. Merwe, H. A. Fletcher, H. Mahomed, A. V. Hill, W. A. Hanekom, G. D. Hussey, H. McShane, Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J. Infect. Dis. 198, 544–552 (2008). Abstract/FREE Full Text
↵ H. McShane, A. A. Pathan, C. R. Sander, S. M. Keating, S. C. Gilbert, K. Huygen, H. A. Fletcher, A. V. Hill, Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10, 1240–1244 (2004). CrossRefMedlineWeb of Science
↵ S. D’Souza, V. Rosseels, M. Romano, A. Tanghe, O. Denis, F. Jurion, N. Castiglione, A. Vanonckelen, K. Palfliet, K. Huygen, Mapping of murine Th1 helper T-cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. Infect. Immun. 71, 483–493 (2003). Abstract/FREE Full Text
↵ H. M. Vordermeier, B. Villarreal-Ramos, P. J. Cockle, M. McAulay, S. G. Rhodes, T. Thacker, S. C. Gilbert, H. McShane, A. V. Hill, Z. Xing, R. G. Hewinson, Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect. Immun. 77, 3364–3373 (2009). Abstract/FREE Full Text
↵ R. H. Brookes, P. C. Hill, P. K. Owiafe, H. B. Ibanga, D. J. Jeffries, S. A. Donkor, H. A. Fletcher, A. S. Hammond, C. Lienhardt, R. A. Adegbola, H. McShane, A. V. Hill, Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. PLoS One 3, e2921 (2008). CrossRefMedline
↵ T. J. Scriba, M. Tameris, N. Mansoor, E. Smit, L. van der Merwe, F. Isaacs, A. Keyser, S. Moyo, N. Brittain, A. Lawrie, S. Gelderbloem, A. Veldsman, M. Hatherill, A. Hawkridge, A. V. Hill, G. D. Hussey, H. Mahomed, H. McShane, W. A. Hanekom, Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur. J. Immunol. 40, 279–290 (2010). MedlineWeb of Science
↵ S. Abdulla, R. Oberholzer, O. Juma, S. Kubhoja, F. Machera, C. Membi, S. Omari, A. Urassa, H. Mshinda, A. Jumanne, N. Salim, M. Shomari, T. Aebi, D. M. Schellenberg, T. Carter, T. Villafana, M. A. Demoitié, M. C. Dubois, A. Leach, M. Lievens, J. Vekemans, J. Cohen, W. R. Ballou, M. Tanner, Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N. Engl. J. Med. 359, 2533–2544 (2008). CrossRefMedlineWeb of Science
↵ M. Walther, F. M. Thompson, S. Dunachie, S. Keating, S. Todryk, T. Berthoud, L. Andrews, R. F. Andersen, A. Moore, S. C. Gilbert, I. Poulton, F. Dubovsky, E. Tierney, S. Correa, A. Huntcooke, G. Butcher, J. Williams, R. E. Sinden, A. V. Hill, Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein. Infect. Immun. 74, 2706–2716 (2006). Abstract/FREE Full Text
↵ V. S. Moorthy, E. B. Imoukhuede, S. Keating, M. Pinder, D. Webster, M. A. Skinner, S. C. Gilbert, G. Walraven, A. V. Hill, Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J. Infect. Dis. 189, 2213–2219 (2004). Abstract/FREE Full Text
↵ B. Watson, A. Cawein, B. L. McKee, J. G. Hackell, Safety and immunogenicity of acellular pertussis vaccine, combined with diphtheria and tetanus as the Japanese commercial Takeda vaccine, compared with the Takeda acellular pertussis component combined with Lederle’s diphtheria and tetanus toxoids in two-, four- and six-month-old infants. Pediatr. Infect. Dis. J. 11, 930–935 (1992). MedlineWeb of Science
↵ F. Zepp, A. Schuind, C. Meyer, R. Sänger, A. Kaufhold, P. Willems, Safety and reactogenicity of a novel DTPa-HBV-IPV combined vaccine given along with commercial Hib vaccines in comparison with separate concomitant administration of DTPa, Hib, and OPV vaccines in infants. Pediatrics 109, e58 (2002). Abstract/FREE Full Text
↵ L. Bungener, F. Geeraedts, W. Ter Veer, J. Medema, J. Wilschut, A. Huckriede, Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 26, 2350–2359 (2008). CrossRefMedlineWeb of Science
↵ D. Spazierer, H. Skvara, M. Dawid, N. Fallahi, K. Gruber, K. Rose, P. Lloyd, S. Heuerding, G. Stingl, T. Jung, T helper 2 biased de novo immune response to Keyhole Limpet Hemocyanin in humans. Clin. Exp. Allergy 39, 999–1008 (2009). CrossRefMedlineWeb of Science
↵ A. K. Abbas, K. M. Murphy, A. Sher, Functional diversity of helper T lymphocytes. Nature 383, 787–793 (1996). CrossRefMedline
↵ J. L. Flynn, J. Chan, K. J. Triebold, D. K. Dalton, T. A. Stewart, B. R. Bloom, An essential role for interferon γ in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178, 2249–2254 (1993). Abstract/FREE Full Text
↵ M. J. Newport, C. M. Huxley, S. Huston, C. M. Hawrylowicz, B. A. Oostra, R. Williamson, M. Levin, A mutation in the interferon-γ–receptor gene and susceptibility to mycobacterial infection. N. Engl. J. Med. 335, 1941–1949 (1996). CrossRefMedlineWeb of Science

Acknowledgments: We thank the Gambian government, the EPI program of Gambia, and staff of Sukuta Health Centre for their collaboration. We thank K. Flanagan, J. Adetifa, and the Sukuta field team for assisting us in this trial. We appreciate M. Sonko, K. Manneh, and S. Sanneh for their field work and A. Bojang and J. Sutherland for laboratory assistance. We also thank K. Bojang for safety monitoring; V. Thomas and J. Mueller for internal monitoring and support; A. Lawrie for coordination; S. Vermaak for help with data analysis; and C. McKenna for study monitoring. We are grateful to the parents and guardians who allowed their infants to participate in this trial. Funding: The study was funded by the Medical Research Council (UK) and the European Commission (EU 6th Framework; TBVAC). Neither funder had any role in the design of the study or the preparation of the manuscript. H.M. is a Wellcome Trust Senior Clinical Research Fellow, and A.V.S.H. is a Wellcome Trust Principal Research Fellow. Author contributions: M.O.C.O., H.M., A.V.S.H., S.R.-J., and R.A.A. designed the study. A.A.O., O.A.O., M.O.C.O., R.A.A., and S.R.-J. provided clinical help. M.O.C.O., A.A.O., N.J.B., and H.M. managed the project. P.K.O., M.O.C.O., H.M., A.V.S.H., and R.A.A. performed laboratory assays and analysis. N.W., S.D., N.J.B., H.M., and M.O.C.O. performed the statistical analysis. M.O.C.O., H.M., N.J.B., A.A.O., O.A.O., A.V.S.H., S.D., N.W., S.R.-J., and R.A.A. wrote the manuscript. Competing interests: A.V.S.H. and H.M. are named inventors on a patent filing related to MVA85A (International patent number WO 2006/072787 A1: Compositions for immunising against mycobacteria), and are shareholders in a joint venture, Oxford-Emergent Tuberculosis Consortium, formed for the future development of this vaccine. The other authors declare that they have no competing interests.



- Posted using BlogPress from my iPad

segunda-feira, 27 de junho de 2011

Caso Clinico New England Journal of Med

Presentation of Case

Dr. Ana A. Weil (Medicine): A 4-year-old Haitian boy was admitted to a hospital in Haiti affiliated with this hospital because of vomiting and diarrhea of 10 hours' duration.

The patient had been well until approximately midnight the night before admission, when vomiting and diarrhea developed. After approximately 6 hours of symptoms, his parents brought him to the hospital by motorcycle taxi, traveling for 4 hours. On arrival, 10 hours after the onset of symptoms, episodes of vomiting and diarrhea were too numerous to count.

The patient's parents said that he had not urinated for hours. He had reportedly previously been healthy. He lived in a small village in Haiti with his parents and sibling. His 8-year-old brother had had mild diarrhea the previous day.

On examination, the patient seemed irritable and was rapidly drinking offered liquids. The pulse was low volume, at a rate of 150 beats per minute; the respirations were shallow, without retractions, at a rate of 45 breaths per minute; and the skin was not hot to the touch. The blood pressure and temperature were not obtained because of lack of equipment. The weight was estimated at 15 kg. The eyes were sunken, skin recoil was less than 1 second but not instantaneous, capillary refill was 2 seconds, and the skin and mucous membranes were dry. The lungs were clear, and there was mild abdominal tenderness. During the examination, the patient passed a clear, watery stool. He was admitted to the hospital, where he shared a cot with a pediatric patient who had similar symptoms, including diarrhea.

A reduced-osmolarity oral rehydration solution (ORS) consisting of glucose, sodium chloride, potassium chloride, and trisodium citrate dihydrate (with 75 mmol of glucose per liter, 75 mmol of sodium per liter, 20 mmol of potassium per liter, 65 mmol of chloride per liter, and 10 mmol of citrate per liter), with a total osmolarity of 245 mmol per liter, was administered. During the next hour, two episodes of vomiting and numerous episodes of diarrhea occurred.

On reexamination 1 hour after the initiation of treatment, the patient had ingested less than 200 ml. He was combative and pushed away the ORS. The pulse was weak, and the hands and feet were cool and clammy. Simultaneous attempts at insertion of intravenous catheters in the antecubital region and the hand were unsuccessful; the patient became increasingly obtunded.

On the third attempt at intravenous access, a catheter was inserted into the saphenous vein of the foot. A bolus (500 ml) of isotonic crystalloid solution containing sodium chloride, sodium lactate, potassium chloride, and calcium chloride was administered, with manual pressure applied to the bag. The patient remained lethargic. Dextrose (30 ml of a 20% solution) was administered rapidly into the intravenous catheter, without improvement in mental status. A second intravenous catheter was placed in the right antecubital region. Another bolus (500 ml) of crystalloid solution was infused during a 30-minute period, with improvement in the level of consciousness, followed by a second liter of the solution during the next 2 hours.

Approximately 4 hours after presentation, episodes of diarrhea were occurring too often to count, the frequency of vomiting had decreased, and no urine output had occurred. On examination, the patient was eagerly drinking ORS, and his mental status was markedly improved. The eyes remained sunken, and skin turgor was slightly decreased from normal. Azithromycin (300 mg) was administered orally. His family was encouraged to have the patient consume 200 ml of ORS per stool produced. During the next 4 hours, he had at least six episodes of diarrhea and drank approximately 400 ml of ORS; 1 liter of the crystalloid solution was administered intravenously. Eight hours after presentation, the total intravenous intake was 3 liters, or approximately 200 ml per estimated kilogram of body weight. He had urinated twice. On examination, there were no signs of dehydration, the pulse was 100 beats per minute, and the respiratory rate was 30 breaths per minute, without rales or cough. During the remainder of the first day, an additional liter of intravenous solution was administered (a total of 4 liters during 24 hours, or approximately 267 ml per kilogram). Overnight, the frequency of diarrhea decreased, with an estimated 10 stools and no vomiting. Oral intake included less than 200 ml of ORS and some broth.

On the morning of the second day, the patient's parents reported that he had cramping in his legs. On examination, signs of dehydration were present, including sunken eyes and slightly decreased skin turgor, with mild abdominal distention and tenderness. A bolus (500 ml) of crystalloid was administered intravenously over a period of 4 hours, and an educator was assigned to assist his parents in understanding the importance of ORS intake. During the next 4 hours, he consumed approximately 800 ml of ORS without vomiting. Signs of dehydration resolved, and abdominal distention decreased. Infusions of intravenous fluid were decreased to minimal flow. His parents were instructed again to match stool output by administering approximately 200 ml of ORS per stool, and his diet was increased to include meals of chicken broth and mashed bananas.

During the second night, three episodes of diarrhea occurred, and another episode between 8 a.m. and 2 p.m. On the third morning, the patient successfully consumed meals of solid food and ORS. He was discharged after 2.5 days, with instructions to the parents about oral hydration, point-of-use water sterilization, and hand sanitation with soap. One week after discharge, a diagnostic test result was received.

Differential Diagnosis

Dr. Jason B. Harris: I participated in the care of this child who presented with acute watery diarrhea during the second week of a cholera epidemic in Haiti, which began in October 2010 and is ongoing. The patient was admitted to a cholera treatment center that was established the previous week and was providing care for more than 100 patients daily who had diarrhea and, in many cases, other concomitant illnesses. No laboratory facilities were available. Like the vast majority of patients with diarrhea in developing countries, no specific laboratory diagnosis was made in this case.

The patient presented with a common problem. Children in developing countries have a median of three episodes of diarrhea annually,1 and diarrheal illness is the second leading cause of death among children, resulting in 1.6 million to 2.1 million deaths annually.2 Before the recent cholera epidemic, an average of 1 of every 93 children born in Haiti died from diarrheal illness before reaching their fifth birthday.3 For this child, the focus is on empirical management of the acute watery diarrhea, not on extensive clinical or laboratory investigations. Algorithms, such as those developed by the World Health Organization (WHO),4 are helpful in managing diarrheal illness in children in resource-limited communities.

Differential Diagnosis of Diarrheal Illness

The first step in the care of this patient is to classify the type of diarrheal illness (Table 1). Diarrhea lasting for more than 14 days is classified as persistent diarrhea. Persistent diarrhea is caused by a distinct set of organisms and is associated with malnutrition and chronic enteropathy. Persistent diarrhea should raise suspicion for underlying infection with the human immunodeficiency virus (HIV); in HIV-infected persons, unexplained persistent diarrhea is a defining illness of the acquired immunodeficiency syndrome.5

Table 1


Classification and Common Causes of Childhood Diarrhea in Developing Countries.

Since our patient had acute diarrhea, the next step is to classify the diarrhea as invasive (bloody) or noninvasive (watery). Invasive diarrhea is defined by grossly bloody or melanotic stools. Most patients with invasive diarrhea have fever and mucus in the stool. Shigella species are the predominant cause of invasive diarrheal illness in children in developing countries,6,7 and empirical management of the illness should include antibiotics aimed at treating and preventing complications of shigellosis.

This child passed watery stools without blood and did not have a tactile fever. The most common causes of acute watery diarrhea are rotavirus in infants and enterotoxigenic Escherichia coli in children.6 There is increasing recognition of the role of caliciviruses in causing gastroenteritis in children and also in adults. Many acute systemic illnesses (e.g., measles, dengue fever, and malaria) may also present with diarrhea.

Cholera

In this case, cholera was suspected because the patient presented during a known epidemic. It is important to distinguish cholera from the other causes of noninvasive diarrhea. A rapid and simple laboratory test for Vibrio cholerae is dark-field microscopy, which, when positive, reveals characteristically darting bacteria. However, in resource-limited communities, the diagnosis of cholera is most often based on clinical suspicion that takes into account the local epidemiology of diarrheal illness. Although mild illness caused by V. cholerae is clinically indistinguishable from other causes of diarrhea, severe cholera is associated with greater losses of fluid and electrolytes than is seen with other causes of noninvasive diarrhea. Furthermore, patients with cholera benefit from the early administration of appropriate antibiotics. Finally, cholera can cause large epidemics.

A classic finding in cholera is “rice water” stool (Figure 1D), which may contain more than 1 billion (109) organisms per milliliter. Patients with severe cholera may shed more than 10 trillion (1013) organisms per day.8 Although many V. cholerae serogroups have been identified in the environment, only serogroups O1 and O139 have caused epidemic cholera. V. cholerae O1, biotype El Tor, is the cause of the current global pandemic of cholera, which began in 1961. Emerging strains, termed “hybrid” or “variant” V. cholerae O1 El Tor, are the causes of more recent epidemics, including the current epidemic in Haiti.9 These variant strains appear to combine the enhanced ability of the El Tor biotype to persist in the environment with the greater virulence associated with the previously circulating classical biotype.

Figure 1


Pathogenesis of Cholera.

This case illustrates the manifestations of severe cholera, or cholera gravis. Epidemic strains of V. cholerae produce cholera toxin — a toxin resulting from the ribosylation of adenosine diphosphate — which causes chloride secretion and the loss of sodium and water into the lumen of the small intestine (Figure 1C). Stool losses in cholera are typically isotonic, and the mean sodium concentration in the stool of children with cholera is double that seen in the diarrhea of children without cholera (Table 2).

Table 2


Chemical Composition of Diarrheal Stool and Therapeutic Solutions.

Dehydration and Rehydration

In cases of rapid fluid losses, the large intestine's capacity for reabsorption is overwhelmed and death may occur within hours. The WHO has provided guidelines for using the physical examination to estimate dehydration in children; laboratory tests provide little additional useful information.4 This patient had deeply sunken eyes, markedly decreased skin turgor, a weak pulse, and mental-status changes, suggesting a 10% loss of fluid per kilogram of body weight within 12 hours after the onset of symptoms. This is typical of severe cholera. During the first weeks of the cholera epidemic in Haiti, deaths occurred in the community a median of 12 hours after the onset of symptoms.11 Children with severe cholera typically present with 5 to 10% dehydration but have additional stool losses that may exceed 20% of their body weight during the first 48 hours after admission.12 Rehydration is the cornerstone of care for patients with cholera, but nutritional interventions, the appropriate use of antibiotics, and recognition of common complications and coexisting conditions are also important.

Rehydration requires the rapid replacement of the initial deficit and ongoing losses with isotonic fluids. Therapeutic fluids for patients with cholera are shown in Table 2. In the United States and other developed countries, a typical approach to a child with dehydration is to use hypotonic solutions to replace estimated fluid and electrolyte deficits slowly over a 24-hour period. In resource-limited locations such as Haiti, children with diarrheal illness often present later, with more severe dehydration, and require more rapid rehydration with isotonic solutions, particularly patients with cholera. With optimal fluid management, the mortality associated with severe cholera is less than 0.2%.10 However, case fatality rates are usually higher in epidemic cholera,13 especially during the early stages, when there are obstacles to providing appropriate clinical care.14 This case illustrates some of the barriers to providing optimal rehydration therapy. Ideally, oral rehydration therapy is initiated at the onset of illness, in the home or in the community.4 This requires the local availability, knowledge, and acceptance of oral rehydration therapy. In this case, had ORS been used at the onset of illness, instead of 10 hours after the onset of symptoms, it is unlikely that life-threatening shock would have occurred during the patient's hospitalization.

For patients with severe dehydration, intravenous fluids are required immediately. Lactated Ringer's solution is the best and most widely available commercial intravenous fluid for cholera. Ideally, the entire fluid deficit should be replaced within 3 to 4 hours after the initiation of therapy in both children and adults.4,15 This patient required more than 300 ml per kilogram of isotonic intravenous and oral fluids to restore euvolemia during the first 28 hours of therapy, which is indicative of a rate of purging that is consistent with severe cholera.

Providing adequate volumes of isotonic fluids to patients with such massive ongoing losses is also a challenge, especially for health care workers who are unfamiliar with the fluid requirements of patients with severe cholera. Cholera cots were assembled at this cholera treatment center and generally are useful for recording stool output (Figure 2). Because of space constraints, this patient shared a cholera cot and bucket with other patients; therefore, a reliable record of the patient's stool output was not made. However, ongoing losses can be estimated at 10 to 20 ml per kilogram per stool, and the volume of these losses can be added to the amount of fluids needed during the initial rehydration period. In this case, euvolemia was initially restored after 8 hours and approximately 200 ml per estimated weight in kilograms; however, had such rapid ongoing losses been factored in, the fluid could have been restored more rapidly, ideally within a 3-to-4-hour window.

Figure 2


Cholera Cot.

Recurrent dehydration, leg cramps, and abdominal distention developed in this patient approximately 12 hours after the initial correction of his fluid deficit. Hypokalemia was the most likely cause of the leg cramps and abdominal distention. Hypokalemia is an important cause of death in patients with diarrheal illness who die after initial rehydration therapy.16 In this case, the hypokalemia and the recurrent dehydration might have been prevented if oral rehydration therapy had been used to replace ongoing diarrheal losses. Oral rehydration therapy provides more potassium than intravenous lactated Ringer's solution and is preferred over intravenous therapy whenever possible. Similarly, the resumption of normal feeding should also begin as soon as possible, to prevent the sequelae of malnutrition and such complications as hypokalemia and hypoglycemia.

Antibiotic Therapy

This patient received azithromycin early during his hospitalization, which is an appropriate treatment for the V. cholerae strain that is circulating in Haiti. Antibiotics can lead to reductions of more than 50% in stool volume and in the duration of diarrhea, from more than 4 days to 2 days. Antibiotics also reduce the shedding of viable V. cholerae from more than 6 days to slightly more than 1 day. This treatment can be useful on a patient-by-patient basis and also facilitates more rapid discharge from cholera treatment centers, thus conserving resources for other patients.17

After rehydration and antibiotic therapy, the next tier of care is to provide nutritional support and to recognize common complications and coexisting conditions seen in patients with cholera. Zinc supplementation (10 mg per day for infants less than 6 months of age and 20 mg per day for 10 days for children 6 months to 5 years of age) should be provided to reduce the severity and duration of childhood diarrheal illness in countries, such as Haiti, where zinc deficiency is common.4,18 Zinc has the added benefit of reducing the incidence of subsequent episodes of diarrhea for several months. In developing countries, children with diarrhea, such as this patient, are also at high risk for vitamin A deficiency and should receive supplementation with vitamin A. Patients with clinical signs of vitamin A deficiency should receive a three-dose series of treatment (50,000 IU for infants <6 months of age, 100,000 IU for infants 6 to 12 months of age, and 200,000 IU for children >12 months of age). In this case, neither zinc nor vitamin A was available. In endemic areas, coexisting conditions, such as pneumonia and sepsis, are a leading cause of death in patients with cholera.19 Therefore, reevaluation for clinical signs of pneumonia and sepsis after rehydration is important. In this case no such conditions were identified on sequential examinations after rehydration.

Dr. Jason B. Harris's Diagnosis

Life-threatening diarrheal illness due to Vibrio cholerae.

Pathological Discussion

Dr. Mary Jane Ferraro: The specimen that we received in the laboratory was from a different child in Haiti who had a similar illness at the same time as this child's illness. The isolate that we obtained was identified in our laboratory as V. cholerae. Susceptibility testing was performed and showed that the isolate was susceptible to tetracycline and azithromycin and was resistant to sulfa drugs and nalidixic acid. This isolate is undoubtedly the same one that had infected our patient, and this result confirms the diagnosis of cholera. Dr. Harris, can you tell us about the additional molecular characterization that was performed on this isolate?

Dr. Harris: At the onset of the epidemic, the initial isolates were rapidly identified as V. cholerae O1, serotype Ogawa, by the National Public Health Laboratory in Haiti. The Centers for Disease Control and Prevention (CDC) subsequently reported that these were hybrid strains of V. cholerae O1, biotype El Tor.9 These are strains that produce the more virulent toxin that is associated with the previously circulating classical biotype of cholera. To determine the phylogeny of the organism, the isolate that Dr. Ferraro described underwent complete genome sequencing. Analysis of variable regions in the organism's genome placed the isolate in the context of other known isolates in V. cholerae and showed that this was a seventh pandemic strain of V. cholerae O1 El Tor and that it was most closely related to isolates obtained in Bangladesh in the past decade.20 These phylogenetic comparisons were based on a single nucleotide variation in selected genes and in the content of selected hypervariable regions in both V. cholerae chromosomes. The isolate was distantly related to strains that had circulated in South America in the early 1990s and strains that are known to cause sporadic V. cholerae in the U.S. Gulf Coast.

The Haitian Cholera Outbreak

Dr. Eric S. Rosenberg (Pathology): Dr. Louise Ivers is with us by telephone from Port-au-Prince, Haiti. Dr. Ivers, would you give us an update on the status of the epidemic there and the responses to the crisis?

Dr. Louise C. Ivers: This patient presented during the second week of the cholera epidemic in Haiti, which began in October 2010. We know now that the first cases came from the center of the country, but the cases that alerted authorities to the epidemic occurred in the large coastal town of Saint-Marc, 2 hours north of the capital city of Port-au-Prince. At the time of this conference, 4 months later, the epidemic continued to evolve. As of April 8, 2011, more than 248,657 cases of cholera had been treated and 4524 patients had died. There continue to be mini-peaks of cases reported, particularly in areas with poor road access and in rural isolated communities that traditionally have limited access to any health services. The number of new cases has decreased substantially since the early phase of the epidemic and now remains relatively stable. Thus, the epidemic has not ended yet, and as the rainy season approaches, the number of cases may increase.

Sanitation and Clean Water

In Haiti, access to clean water is lacking for the majority of the population, as it most likely was for this patient's family. Almost a decade ago, Haiti ranked the worst of 147 countries in terms of water resources, and little has happened since then to substantially improve services and infrastructure. Few households have access to a formal latrine. Housing and shelter, which were inadequate in rural Haiti before the earthquake of 2010, became even less sufficient when persons who were displaced by the earthquake moved to stay with family and friends in already overcrowded and often poorly constructed housing in the countryside. Many rural homes in Haiti are subject to flooding during the rainy season, even during moderate rainfall, and most have dirt floors, which increase the challenges of sanitation and hygiene.

Response to the Outbreak

The outbreak of cholera, the likes of which had never been seen by the current population of Haiti, caused huge pressure on what was already a weak public health infrastructure. Initially, the causes and methods of transmission of cholera were poorly understood by those at risk, and clean water and soap were not widely available in the areas affected; these two issues in the context of poor access to services led to high initial mortality rates. This patient exemplifies this problem: he did not have access to oral rehydration early enough to prevent severe complications. The learning curve for institutions and providers with no cholera experience was steep. In view of these challenges, the response to the outbreak was relatively fast. Cholera treatment centers were erected, and efforts were made to establish temporary solutions to the problem of the lack of potable water and to introduce hygiene measures. There has been a strong response from the government of Haiti and national and international partners, and there are now more than 400 cholera treatment facilities, such as the one that this patient entered and that saved his life.

As the months have passed, the training of service providers, access to services for patients, water-treatment education and supplies, and education in the community have all increased, contributing to increased survival and a reduction in the number of new cases of cholera. Institutional mortality nationwide, originally as high as 7 or 8%, has fallen to less than 2%. This patient's family was given instructions in water purification and hand hygiene at the time of the patient's discharge. They were also given supplies so they could put their education into practice. However, challenges remain. Rural isolated communities have poor access to health services in general; poor living conditions, lack of sanitation, and lack of access to clean water persist as a result of dire poverty.

Dr. Rosenberg: What is the likelihood that cholera will be eradicated from Haiti?

Dr. Edward T. Ryan (Infectious Diseases): We have learned from previous cholera outbreaks that once this organism gets a foothold in the water supply in impoverished areas, it is almost impossible to eradicate.

Anatomical Diagnosis

Vibrio cholerae O1 (toxigenic), serotype Ogawa (testing performed at the CDC).

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

This case was presented at the Medicine Grand Rounds, February 17, 2011.

We thank Dr. Lawrence Ronan for helpful input.

References

M Kosek, C Bern, RL GuerrantThe global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000.Bull World Health Organ2003;81:197-204
C Boschi-Pinto, L Velebit, K ShibuyaEstimating child mortality due to diarrhoea in developing countries.Bull World Health Organ2008;86:710-717
World health statistics 2010. Geneva: World Health Organization, 2010.
The treatment of diarrhea: a manual for physicians and other senior health workers, 4th revision. Geneva: World Health Organization, 2005. (WHO/FCH/CAH/05.1.)
WHO case definitions of HIV for surveillance and revised clinical staging and immunologic classification of HIV-related disease in adults and children. Geneva: World Health Organization, 2007.
S Huilan, LG Zhen, MM Mathan, Etiology of acute diarrhoea among children in developing countries: a multicentre study in five countries.Bull World Health Organ1991;69:549-555
KL Kotloff, JP Winickoff, B Ivanoff, Global burden of Shigella infections: implications for vaccine development and implementation of control strategies.Bull World Health Organ1999;77:651-666
EJ Nelson, JB Harris, JG Morris, SB Calderwood, A CamilliCholera transmission: the host, pathogen and bacteriophage dynamic.Nat Rev Microbiol2009;7:693-702
Update: cholera outbreak -- Haiti, 2010.MMWR Morb Mortal Wkly Rep2010;59:1473-1479[Erratum, MMWR Morb Mortal Wkly Rep 2010;59:1556.]
DA Sack, RB Sack, GB Nair, AK SiddiqueCholera.Lancet2004;363:223-233
Update: outbreak of cholera -- Haiti, 2010.MMWR Morb Mortal Wkly Rep2010;59:1586-1590
D Mahalanabis, CK Wallace, RJ Kallen, A Mondal, NF PierceWater and electrolyte losses due to cholera in infants and small children: a recovery balance study.Pediatrics1970;45:374-385
JB Harris, RC Larocque, RC Charles, RN Mazumder, AI Khan, PK BardhanCholera's western front.Lancet2010;376:1961-1965
DA Walton, LC IversResponding to cholera in post-earthquake Haiti.N Engl J Med2011;364:3-5
Cholera Outbreak Training and Shigellosis (COTS) Program home page. (http://www.cotsprogram.com.)
T Butler, M Islam, AK Azad, MR Islam, P SpeelmanCauses of death in diarrhoeal diseases after rehydration therapy: an autopsy study of 140 patients in Bangladesh.Bull World Health Organ1987;65:317-323
EJ Nelson, DS Nelson, MA Salam, DA SackAntibiotics for both moderate and severe cholera.N Engl J Med2011;364:5-7
Management of severe malnutrition: a manual for physicians and other senior health workers. Geneva: World Health Organization, 1999.
ET Ryan, U Dhar, WA Khan, Mortality, morbidity, and microbiology of endemic cholera among hospitalized patients in Dhaka, Bangladesh.Am J Trop Med Hyg2000;63:12-20
CS Chin, J Sorenson, JB Harris, The origin of the Haitian cholera outbreak strain.N Engl J Med2011;364:33-42
Source Information

From the Departments of Infectious Diseases (J.B.H.) and Pathology and Microbiology (M.J.F.), Massachusetts General Hospital; the Department of Medicine, Brigham and Women's Hospital (L.C.I.); and the Departments of Pediatrics (J.B.H.), Medicine (L.C.I.), and Pathology (M.J.F.), Harvard Medical School — all in Boston.